Resources

This week saw the publication of Engineering Biology Aspirations, the final output of Angela McLean’s Year of Engineering Biology. The report sets out an ambitious, forward-looking vision for the field, exploring how engineering biology could shape the future of everything from food and fashion to fuel and health.

In this blog, Michelle Mitchell, CEO of Cancer Research UK, talks about West Streeting recent visit to the Bowelbabe Lab.

Mosaic Therapeutics, Ltd, a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies, announced the in-licensing of two clinical-stage oncology programs.

Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global license agreement.

Sarah Brockbank, Strategy Leader – Complex Medicines at Medicines Discovery Catapult, shares insight into a new regulatory roadmap created by the UK’s Intracellular Drug Delivery Centre (IDDC).

Washington’s shifting policy landscape continues to cause uncertainty, while the UK is staying calm. Join our webinar this Thursday to hear how we’re engaging with international partners and government to ensure the UK voice is heard and our sector remains robust.

The UK pavilion at SynBioBeta 2025 will unite leading UK engineering biology companies and ecosystem partners to highlight the UK’s world-class strengths in engineering biology.

Amid ongoing geopolitical uncertainty, the UK life sciences ecosystem is keeping calm and carrying on.

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces a partnership with the NHS Cancer Vaccine Launch Pad (CVLP) to fast-track access for NHS patients into the fourth cohort of the Company’s Phase 2 clinical SCOPE study. 

Myricx Bio (‘Myricx’ is pleased to announce team expansion, with the appointment of Steen Lisby, M.D., D.MSc. as CMO and Jesper Valbjørn, M.Sc. as SVP CMC.

eXmoor Pharma, a full-service Cell and Gene Therapy (CGT) CDMO, has appointed Dr James Miskin as Non-Executive Director.

The agreement is expected to serve as a critical foundation for activating international joint research, academic exchange and research collaboration in quantum fields, including quantum computing.

Coulter Partners successfully completed a search assignment for iOnctura and is pleased to announce the placement of Dr. Mark Velleca as Chair of the Board of Directors.

The workshop brought together leading academic researchers, industry experts and innovators to explore the fundamentals of AlphaFold – an artificial intelligence (AI) program developed by Google DeepMind to predict the 3D structure of proteins.

In this blog, Dr Emma Lawrence, Head of data tech policy and public affairs at BIA, writes about the UK government's recent £600 million initiative to launch a Health Data Research Service which aims to revolutionize access to NHS data and tackle longstanding governance and technical hurdles.

Brainomix 360 unlocks expert-level insights from universally available non-contrast CT scans, helping stroke networks expand access to life-changing treatments.